AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Viridian Therapeutics Inc (NASDAQ:VRDN)
16.35 USD
+0.480 3.025%| Previous Close (in USD) | 15.87 |
|---|---|
| Change | +0.480 3.025% |
| 52 W H/L (in USD) | 28.350/10.925 |
| EBITDA (in USD) | -237.312M |
| PE Ratio | -- |
| Volume | 1684879 |
| Diluted Eps TTM | -4.49 |
| Total Assets (in USD) | 490.424M |
|---|---|
| Total Liabilities (in USD) | 48.402M |
| Revenue TTM (in USD) | 0.288M |
| Cash (in USD) | 102.827M |
| Market Cap (in USD) | 772.890 M |
| Revenue Per Share TTM | 0.006 |
| Gross Profit TTM (in USD) | -99.122M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Viridian Therapeutics Inc
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
221 Crescent Street, Waltham, MA, United States, 02453
617 272 4600
Employees: 94
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Jonathan Violin M.B.A., Ph.D. | Co-Founder, CEO, Pres & Director | 1975 |
| 2. | Mr. Kristian Humer M.B.A. | CFO, Chief Bus. Officer, Principal Financial Officer & Principal Accounting Officer | 1975 |
| 3. | Dr. Barrett Katz CMO, M.B.A., M.D., MBA | Chief Medical Officer | 1950 |
| 4. | Dr. Eric N. Olson Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | NA |
| 5. | Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder & Member of the Scientific Advisory Board | 1945 |
| 6. | Dr. Marvin H. Caruthers Ph.D. | Co-Founder & Scientific Advisory Board Member | 1940 |
| 7. | Mr. Vahe Bedian Ph.D. | Co-Founder & Scientific Advisor | NA |
| 8. | Ms. Carrie Melvin M.B.A. | Chief Operating Officer | NA |
| 9. | Dr. Rob Henderson Ph.D. | Chief Scientific Officer | NA |
| 10. | Mr. Todd James IRC | Sr. VP of Corp. Affairs & Investor Relations | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -129.874M | -79.413M | -110.715M | -41.873M | -32.703M |
| Minority Interest | - | - | - | - | - |
| Net Income | -125.444M | -79.416M | -110.984M | -42.42M | -32.703M |
| Selling General Administrative | 35.182M | 25.805M | 13.265M | 11.646M | 11.049M |
| Gross Profit | 1.772M | 2.963M | 1.05M | 4.461M | 8.386M |
| Reconciled Depreciation | 0.255M | 0.12M | 0.239M | 0.288M | 0.281M |
| Ebit | -134.304M | -79.728M | -110.38M | -41.979M | -32.111M |
| Ebitda | -129.388M | -79.29M | -40.346M | -41.038M | -31.83M |
| Depreciation And Amortization | 4.916M | 0.438M | 70.034M | 0.941M | 0.281M |
| Operating Income | -134.304M | -79.728M | -110.38M | -41.979M | -33.084M |
| Other Operating Expenses | 136.076M | 82.691M | 41.569M | 46.44M | 41.47M |
| Interest Expense | 0.486M | 0.003M | 0.508M | 0.835M | 0.873M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 4.916M | 0.318M | 0.173M | 0.941M | 1.254M |
| Net Interest Income | 4.43M | 0.315M | -0.335M | 0.106M | 0.381M |
| Income Tax Expense | -4.43M | 0.003M | 0.269M | 0.547M | 1.254M |
| Total Revenue | 1.772M | 2.963M | 1.05M | 4.461M | 8.386M |
| Total Operating Expenses | 136.076M | 82.691M | 41.569M | 46.44M | 41.47M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 4.43M | 0.315M | -0.335M | 0.106M | 0.381M |
| Net Income From Continuing Ops | -130.107M | -79.562M | -110.715M | -41.873M | -32.703M |
| Net Income Applicable To Common Shares | -129.874M | -79.413M | -110.715M | -41.873M | -32.703M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 490.424M | 435.091M | 203.709M | 131.255M | 30.262M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 9.006M | 6.521M | 2.747M | 1.972M | 2.786M |
| Total Liab | 48.402M | 40.027M | 15.993M | 11.218M | 14.508M |
| Total Stockholder Equity | 442.022M | 395.064M | 187.716M | 120.037M | 15.754M |
| Other Current Liab | 23.265M | 18.214M | 10.498M | 9.248M | 0.1M |
| Common Stock | 0.54M | 0.414M | 0.239M | 0.042M | 0.349M |
| Capital Stock | 207.056M | 142.561M | 134.072M | 180.843M | 0.349M |
| Retained Earnings | -725.908M | -488.174M | -358.3M | -278.887M | -168.169M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.982M | 318.131M | 1.335M | - |
| Cash | 102.827M | 155.579M | 42.299M | 45.897M | 24.846M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 26.635M | 33.349M | 13.636M | 10.674M | 10.18M |
| Current Deferred Revenue | 0.288M | 0.288M | 0.289M | 0.301M | 5.008M |
| Net Debt | -81.779M | -150.321M | -41.779M | -45.442M | -16.542M |
| Short Term Debt | 0.843M | 0.613M | 0.52M | 0.455M | 3.976M |
| Short Long Term Debt | - | - | - | - | 3.976M |
| Short Long Term Debt Total | 21.048M | 5.258M | 0.52M | 0.455M | 8.304M |
| Other Stockholder Equity | 960.536M | 741.067M | 412.101M | 218.089M | 183.574M |
| Property Plant Equipment | - | 1.326M | 0.375M | 0.787M | 0.523M |
| Total Current Assets | 486.478M | 424.55M | 200.163M | 129.611M | 29.739M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 374.543M | 268.971M | 154.666M | 81.742M | 1.999M |
| Net Receivables | 0.102M | 0.102M | 0.451M | - | 0.108M |
| Long Term Debt | 20.205M | 4.645M | - | - | 4.328M |
| Inventory | - | -6.623M | - | - | - |
| Accounts Payable | 2.239M | 14.234M | 2.329M | 0.67M | 1.096M |
| Accumulated Other Comprehensive Income | 0.338M | -0.39M | -0.157M | -0.008M | -3.348M |
| Non Currrent Assets Other | 0.604M | 7.605M | 1.491M | 0.857M | - |
| Non Current Assets Total | 3.946M | 10.541M | 3.546M | 1.644M | 0.523M |
| Capital Lease Obligations | 0.843M | 0.613M | 0.52M | 0.455M | - |
| Long Term Debt Total | - | 4.645M | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -114.329M | -74.033M | -50.481M | 28.31M | -29.462M |
| Total Cashflows From Investing Activities | -115.126M | -74.292M | -50.481M | 28.226M | -29.907M |
| Total Cash From Financing Activities | 322.244M | 125.275M | 101.311M | 0.07M | 41.916M |
| Net Income | -129.874M | -79.413M | -110.715M | -41.873M | -32.703M |
| Change In Cash | 113.28M | -3.598M | 21.051M | -7.76M | -14.835M |
| Begin Period Cash Flow | 42.299M | 45.897M | 24.846M | 32.606M | 47.441M |
| End Period Cash Flow | 155.579M | 42.299M | 45.897M | 24.846M | 32.606M |
| Total Cash From Operating Activities | -93.838M | -54.581M | -29.779M | -36.056M | -26.844M |
| Depreciation | 0.255M | 0.12M | 0.239M | 0.288M | 0.281M |
| Other Cashflows From Investing Activities | - | 0.079M | -0.003M | -0.003M | -0.003M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | -57.795M |
| Sale Purchase Of Stock | 0.183M | 125.275M | 109.922M | - | - |
| Other Cashflows From Financing Activities | 30.633M | 11.033M | 86.5M | 0.12M | -2.613M |
| Capital Expenditures | 0.797M | 0.338M | 0.042M | 0.084M | 0.445M |
| Change In Working Capital | 15.962M | 1.724M | 4.427M | 1.651M | 1.939M |
| Other Non Cash Items | 0.054M | 7.485M | 72.569M | 0.34M | 0.376M |
| Free Cash Flow | -94.635M | -54.919M | -29.821M | -36.14M | -27.289M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Stock Selector Small Cap | 2 years ago | 401927 |
| 2. | SPDR® S&P Biotech ETF | 2 years ago | 3174676 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1766510 |
| 4. | Fidelity Advisor Biotechnology I | 2 years ago | 1284907 |
| 5. | Fidelity Select Health Care | 2 years ago | 1180000 |
| 6. | iShares Russell 2000 ETF | 2 years ago | 1151660 |
| 7. | Fidelity Select Biotechnology | 2 years ago | 1039238 |
| 8. | AB Small Cap Growth A | 2 years ago | 906512 |
| 9. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 828930 |
| 10. | Fidelity Small Cap Growth | 2 years ago | 783200 |
| 11. | Fidelity Series Small Cap Opps | 2 years ago | 774652 |
| 12. | Fidelity Advisor Health Care I | 2 years ago | 750000 |
| 13. | Polar Capital Biotech S Inc | 2 years ago | 750000 |
| 14. | FIAM Small Cap Core Composite | 2 years ago | 728000 |
| 15. | FIAM Small Cap Core CIT Cl B | 2 years ago | 722600 |
| 16. | Strategic Advisers Fidelity US TtlStk | 2 years ago | 615974 |
| 17. | CREF Stock R1 | 2 years ago | 599370 |
| 18. | Pictet-Biotech P USD | 2 years ago | 572269 |
| 19. | Fidelity Small Cap Index | 2 years ago | 436680 |
| 20. | Pictet-Global Megatrend Sel I USD | 2 years ago | 427581 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 2 years ago | 7625542 |
| 2. | Paradigm Biocapital Advisors LP | 2 years ago | 4794488 |
| 3. | Perceptive Advisors LLC | 2 years ago | 3657099 |
| 4. | Deep Track Capital, LP | 2 years ago | 3456053 |
| 5. | BlackRock Inc | 2 years ago | 3426450 |
| 6. | Vanguard Group Inc | 2 years ago | 3234279 |
| 7. | State Street Corporation | 2 years ago | 2708383 |
| 8. | Maverick Capital Ltd | 2 years ago | 2692414 |
| 9. | COMMODORE CAPITAL LP | 2 years ago | 1924074 |
| 10. | Fairmount Funds Management LLC | 2 years ago | 1845813 |
| 11. | AllianceBernstein L.P. | 2 years ago | 1722819 |
| 12. | Vivo Capital, LLC | 2 years ago | 1678207 |
| 13. | Great Point Partners LLC | 2 years ago | 1335000 |
| 14. | Novo A/S | 2 years ago | 1100000 |
| 15. | Pictet Asset Manangement SA | 2 years ago | 1095441 |
| 16. | Geode Capital Management, LLC | 2 years ago | 994468 |
| 17. | Yiheng Capital LLC | 2 years ago | 948130 |
| 18. | Polar Capital Holdings PLC | 2 years ago | 889198 |
| 19. | Goldman Sachs Group Inc | 2 years ago | 763474 |
| 20. | 5AM Venture Management, LLC | 2 years ago | 736595 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...